Nutrition & DietResearch PaperOpen Access

5:2 Intermittent Fasting Protects Muscle and Liver in Obesity via Gut Microbiome

A 5:2 fasting protocol reversed muscle loss and liver fat in obese mice by reshaping gut bacteria and bile acid signaling.

Monday, October 5, 2026 0 views
Published in J Cachexia Sarcopenia Muscle
A split image: on one side a plate with nothing on it representing a fasting day, on the other side a cross-section illustration of muscle fibers and a healthy liver, on a clean lab bench

Summary

Fatty liver disease (MASLD) is common and often comes with weaker muscle. Intermittent fasting helps the liver, but its effect on muscle has been unclear. Researchers gave male mice a high-fat diet for 14 weeks to cause fatty liver. They then put some mice on a 5:2 schedule for 12 weeks: two non-consecutive fasting days a week and unrestricted high-fat food on the other five. The fasting mice ate about the same total calories as the others but weighed less and had healthier livers. They also had stronger grip, larger muscle fibers and less muscle inflammation. Their gut lining was sturdier, blood endotoxin was lower, and gut bacteria shifted toward species that support bile acid signaling. The findings suggest fasting may protect liver and muscle together, but they come from mice and need human testing.

Detailed Summary

Fatty liver disease, now called metabolic dysfunction–associated steatotic liver disease (MASLD), is the most common chronic liver condition worldwide. It often travels with declining muscle quality, which matters for healthspan because strength and muscle mass underpin independence with age. Intermittent fasting is popular for reducing liver fat and body weight, yet its effect on muscle is unclear, and some human data suggest fasting may reduce lean mass. This study asked whether a 5:2 pattern could help both organs at once.

Male C57BL/6J mice ate a 45% high-fat diet (HFD) for 14 weeks to establish MASLD, confirmed by liver histology in five mice per group. The remaining HFD mice were randomized to continuous HFD or a 5:2 regimen (IF5:2) for 12 weeks. IF5:2 meant two non-consecutive fasting days per week with water only and unrestricted HFD on the other five days. A normal chow group served as reference. Mice were sacrificed in the fed state 48 hours after the last fast, so results reflect sustained adaptations rather than acute fasting.

IF5:2 mice overate on refeeding days, yet cumulative food mass, total energy and fat-derived energy intake did not differ from continuous HFD. They still had lower body weight, serum triglycerides, cholesterol, ALT and AST, a lower liver-to-body weight ratio, less Oil Red O lipid staining and less F4/80-positive inflammation. Several fat depots shrank, but brown fat did not. In muscle, IF5:2 increased fiber cross-sectional area versus HFD, raised body-weight-normalized grip strength (n=8) and muscle-to-body weight ratio to chow-like levels, and lowered muscle Il6 and Tnf expression (n=4). Absolute quadriceps mass did not significantly rise.

The gut also changed. HFD thinned the colon wall and reduced Muc2, Tjp1, Cldn4 and Ocln expression. IF5:2 reversed these changes and brought serum LPS down to chow levels (n=4). Metagenomic sequencing (n=6) showed IF5:2 communities clustering closer to chow without changing alpha diversity. Limosilactobacillus reuteri and Faecalibaculum rodentium were enriched, and inflammation-associated Mucispirillum schaedleri was enriched in HFD mice. Secondary bile acid biosynthesis pathways rose, and F. rodentium contributed most to bile salt hydrolase function.

Bile acid signaling appeared more active. Fxr expression rose in intestine and liver. Fgfr4 and Klb rose in liver and muscle, and Tgr5 and Pkaca rose in muscle. The atrophy-related genes Foxo3, Trim63 and Fbxo32 fell. Total free fatty acids in liver and muscle (n=5) dropped to chow levels and correlated negatively with bile acid receptor genes. These are associations at the mRNA level; bile acids themselves were not measured.

For longevity, the data suggest 5:2 fasting may improve the liver without costing muscle quality in this model. Caveats are important: only male mice, small groups, no causal tests of the gut–bile acid–muscle link, and muscle gains partly reflect lower body weight. Human trials with lean mass imaging and strength testing are needed.

Key Findings

  • Cumulative energy and fat intake did not differ between IF5:2 and continuous HFD mice, yet IF5:2 mice had significantly lower body weight despite compensatory overeating on refeeding days
  • IF5:2 significantly lowered serum triglycerides, total cholesterol, ALT and AST, and reduced liver lipid droplet area and F4/80-positive inflammation versus continuous HFD (n=8)
  • Body-weight-normalized grip strength and muscle-to-body weight ratio rose significantly versus HFD and were comparable to chow-fed mice (n=8), though absolute quadriceps mass did not significantly increase
  • Quadriceps fiber cross-sectional area was larger in IF5:2 than HFD mice, and muscle Il6 and Tnf mRNA were significantly lower (n=4)
  • Serum LPS fell to chow-like levels, while colon wall thickness and Muc2, Tjp1, Cldn4 and Ocln expression were restored, indicating improved gut barrier integrity (n=4)
  • Metagenomics (n=6) showed enrichment of Limosilactobacillus reuteri and Faecalibaculum rodentium, depletion of Mucispirillum schaedleri and upregulated secondary bile acid biosynthesis, with alpha diversity unchanged
  • Total free fatty acids in liver and muscle fell to chow levels (n=5) and correlated negatively with bile acid receptor gene expression; muscle atrophy genes Trim63, Fbxo32 and Foxo3 were downregulated

Methodology

Male C57BL/6J mice (7 weeks old at arrival) ate chow or a 45% high-fat diet for 14 weeks to induce MASLD. HFD mice were then randomized by body weight to continuous HFD or IF5:2 (two non-consecutive fasting days weekly) for 12 weeks, and all mice were sacrificed in the fed state. Outcomes included grip strength, serum biochemistry and ELISA (LPS, TNF-α, IL-6), liver, colon and muscle histology, fecal shotgun metagenomics, qRT-PCR and targeted free fatty acid profiling by GC-MS. Group sizes were n=8 for grip strength and serum, n=4 for qPCR and LPS, n=6 for metagenomics and n=5 for fatty acids, analyzed mainly by one-way ANOVA with Tukey's test and Spearman correlations.

Study Limitations

Only male mice were studied, group sizes were small (n=4 to 8) and many findings are mRNA-level or correlational, so causality through the gut microbiota–bile acid–muscle axis was not demonstrated. Bile acid concentrations were not measured, and part of the muscle benefit reflects lower body weight rather than higher absolute muscle mass. Conflict-of-interest details were not available in the supplied text, which was truncated before the discussion.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: